Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Renal Sarcoidosis by Methylprednisolone Bolus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Acute kidney injury with estimated glomerular filtration rate (eGFR) \< 60 mL/min/1,73 m2, defined by an increase of initial value \> 25% or an increase of \> 30 µmol/l, since at least 3 months.~* Sarcoidosis diagnostic criteria according to ATS/ERS/WASOG (Am J Respir Crit Care Med 1999)~* Renal biopsy compatible with renal sarcoidosis :~* Granulomatosis tubulo-interstitial nephropathy and extra-renal damage of histologically proved or suggestive sarcoidosis Or~* Tubulo-interstitial nephropathy without granuloma and extra-renal damage of histologically proved sarcoidosis~* Informed consent~* Patients with social security~Exclusion Criteria:~* Corticosteroids greater than 0,25 mg/kg/j prednisone equivalent~* Introduction of an immunosuppressant in the month before inclusion~* Another cause of renal granulomatosis or tubulo-interstitial nephropathy~* Isolated renal damage without extra-renal past or present damage for a sarcoidosis~* Chronic renal failure, prior sarcoidosis with eGFR \< 30 mL/min/1,73 m2~* Acute renal failure from other causes. If hypercalcaemia is greater than 3 mmol/L, the correction of any dehydration will systematically salt intake, followed of renal function control before inclusion.~* Pregnancy, nursing~* Tuberculosis~* Uncontrolled sepsis~* Uncontrolled psychotic state~* Hypersensibility to methylprednisolone hemisuccinate~* Drugs prescription causing wave burst arrhythmia and/or long QT on ECG

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- oral prednisone (Type: NO_INTERVENTION): Oral prednisone 1 mg/kg/d for 30 days and progressive tapering of steroids, to get 0,5 mg/kg/d at M3 and 0,25 mg/kg/d at M6 and 5-10 mg at M12.
- methylprednisolone bolus (Type: EXPERIMENTAL): methylprednisolone bolus 15 mg/kg/d for 3 days before oral prednisone 1 mg/kg/d for 30 days and progressive tapering of steroids, to get 0,5 mg/kg/d at M3 and 0,25 mg/kg/d at M6 and 5-10 mg at M12.

Based on this trial design, predict the completion outcome and termination type (if applicable).